IPP Bureau
FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease
By IPP Bureau - September 02, 2025
The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease
FDA approves Sanofi’s BTK inhibitor for immune thrombocytopenia
By IPP Bureau - September 02, 2025
ITP is a disease of complex immune dysregulation leading to low platelet counts, bleeding, and reduced quality of life
Fortis takes over 200-bed Greater Noida hospital on long term lease
By IPP Bureau - September 02, 2025
Fortis will assume complete operational and financial control, allowing it to consolidate the hospital's performance within its network
Medanta launches 550-bed super specialty hospital in Noida
By IPP Bureau - September 02, 2025
The hospital opens with 300 operational beds, including 100+ ICU beds and 5 advanced operating theatres
Zydus launches VaxiFlu vaccine for flu protection
By IPP Bureau - September 02, 2025
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
Glenmark Pharmaceuticals USA to launch Eribulin Mesylate injection
By IPP Bureau - September 02, 2025
Glenmark’s Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is bioequivalent and therapeutically equivalent to the reference listed drug, Halaven Injection, 1 mg/2 mL (0.5 mg/mL),of Eisai
Revvity establishes In Vivo Imaging Center of Excellence in North Carolina
By IPP Bureau - September 02, 2025
Facility designed to advance the next generation of imaging systems
India preparing to become hub for medical technology: Pharmaceuticals Secretary
By IPP Bureau - September 01, 2025
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Shukra Pharmaceuticals bags Rs. 24 crore medicines supply contract from HSCC India
By IPP Bureau - September 01, 2025
Zydus Wellness acquires U.K. based Comfort Click for Rs. 2,846 Cr
By IPP Bureau - August 31, 2025
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
GEA, JGC commission new spray dryer at Chugai Pharmaceutical in Japan
By IPP Bureau - August 31, 2025
This PSD-3, the first pharmaceutical spray dryer built by GEA for OEB-5 products, sets new standards for high-containment pharmaceutical spray drying
Bayer presents Phase III VICTOR clinical trial data of vericiguat at ESC Congress 2025
By IPP Bureau - August 31, 2025
The positive benefit-risk profile of vericiguat in its approved indication in patients with HFrEF following a recent heart failure event based on the pivotal Phase III VICTORIA trial remains unchanged
Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran
By IPP Bureau - August 31, 2025
Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives
Novo Nordisk taps Replicate Bioscience’s srRNA platform for obesity
By IPP Bureau - August 31, 2025
Replicate will receive research funding and could potentially receive up to approximately US$550 million
